Download PDF

1. Company Snapshot

1.a. Company Description

SOPHiA GENETICS SA operates as a healthcare technology company.The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.


SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Show Full description

1.b. Last Insights on SOPH

SOPHiA GENETICS SA's recent performance was positively driven by a 16% year-over-year revenue growth to $18.3 million, with a gross margin of 67.0% on a reported basis and 74.4% on an adjusted basis. The company's MSK-ACCESS powered with SOPHiA DDM gain adoption, contributing to the strong quarter. Additionally, a new multi-year collaboration with AstraZeneca to leverage AI Factories for breast cancer therapies and a precision oncology partnership with Jessa Ziekenhuis in Belgium, announced on September 5, 2025, are expected to drive growth.

1.c. Company Highlights

2. SOPHiA GENETICS Delivers Strong Q3 2025 Results with Accelerated Revenue Growth

SOPHiA GENETICS reported a robust financial performance in Q3 2025, with total revenue reaching $19.5 million, representing a 23% year-over-year increase. The company's adjusted gross margin remained strong at 73.1%, while the adjusted EBITDA loss was $10.2 million, up 8% from the prior year. The EPS loss was $0.3, relative to estimates at $0.2. The company's financial performance was driven by its continued expansion across new accounts, growth in the U.S. market, and the increasing adoption of its liquid biopsy application, MSK-ACCESS.

Publication Date: Nov -26

📋 Highlights
  • Revenue Growth Acceleration: 23% YoY increase in Q3 revenue to $19.5 million, with full-year guidance raised to $75–77 million.
  • Customer Expansion: 31 new customers added in Q3, totaling 94 in 2025, exceeding 2024's total of 92.
  • U.S. Market Growth: 30% YoY revenue growth in the U.S., with major health systems like Geisinger and Baylor onboarding.
  • MSK-ACCESS Adoption: 60+ global customers for liquid biopsy application, including partnerships with Myriad Genetics (U.S.) and A.D.A.M. (Japan).
  • Financial Efficiency: Adjusted gross margin remains strong at 73.1%, and adjusted EBITDA improved 13% YoY despite $10.2M loss.

Revenue Growth Drivers

The company's revenue growth was driven by the signing of 31 new customers in Q3, bringing the total to 94 in 2025, surpassing the 92 customers signed in all of last year. The U.S. revenue grew 30% year-over-year, with new customers including Geisinger Health System and Baylor Scott & White Health. As Ross Muken highlighted, "The go-to-market teams are seeing broad and growing demand for the SOPHiA offering." The company's MSK-ACCESS application has signed over 60 customers worldwide since its launch last year.

Operational Highlights

The company expanded its footprint at several top-ranked institutions, including Gustave Roussy and Institut Paoli-Calmettes. The liquid biopsy application, MSK-ACCESS, is being used by over 60 customers worldwide, with about 20% having started to enter routine use. The company expects this to ramp up over the next 1 to 2 quarters, with large accounts coming online in Q4 and Q1 2026. The company's partnership with Myriad Genetics to develop MSK-ACCESS into a regulated companion diagnostic in the U.S. is a significant development.

Valuation and Outlook

With a P/S Ratio of 4.63 and an EV/EBITDA of -5.03, the market is pricing in a certain level of growth for SOPHiA GENETICS. Analysts estimate next year's revenue growth at 15.1%. The company's guidance for 2025 revenue has been raised to $75 million to $77 million, representing growth of 15% to 18%. While the EPS loss was wider than expected, the company's strong revenue growth and expanding customer base are positive indicators. The company's outlook for biopharma R&D spending and overall funding for 2026 is positive, with a strong pipeline of opportunities and recent contract wins.

3. NewsRoom

Card image cap

SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

Nov -11

Source: prnewswire.com

Card image cap

SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine

Nov -11

Source: prnewswire.com

Card image cap

SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript

Nov -04

Source: seekingalpha.com

Card image cap

SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance

Nov -04

Source: prnewswire.com

Card image cap

SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025

Oct -21

Source: prnewswire.com

Card image cap

A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan

Oct -16

Source: prnewswire.com

Card image cap

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

Oct -16

Source: prnewswire.com

Card image cap

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep -23

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (15.10%)

6. Segments

SOPHiA Platform

Expected Growth: 15.1%

The SOPHiA Platform's growth is driven by increasing adoption of precision medicine, advancements in genomic sequencing, and rising demand for personalized healthcare. The platform's cloud-based nature and ability to facilitate genetic research and disease diagnosis will further fuel growth.

Workflow Equipment and Services

Expected Growth: 15.4%

Growing demand for genomic data analysis and interpretation, increasing adoption of precision medicine, and advancements in next-generation sequencing drive the growth of the workflow equipment and services market.

7. Detailed Products

SOPHiA DDM

A comprehensive genomic profiling solution for cancer research and diagnostics

SOPHiA AI

An artificial intelligence-powered analytics platform for genomic data interpretation

SOPHiA Hereditary Cancer

A genetic testing solution for hereditary cancer risk assessment

SOPHiA PGS

A preimplantation genetic screening solution for IVF and reproductive health

SOPHiA NGS

A next-generation sequencing solution for genetic testing and research

8. SOPHiA GENETICS SA's Porter Forces

Forces Ranking

Threat Of Substitutes

SOPHiA GENETICS SA operates in the genomics industry, where the threat of substitutes is moderate. While there are alternative technologies available, SOPHiA GENETICS SA's proprietary algorithms and expertise in genomic data analysis provide a competitive advantage.

Bargaining Power Of Customers

SOPHiA GENETICS SA's customers are primarily hospitals, research institutions, and pharmaceutical companies. These customers have limited bargaining power due to the specialized nature of SOPHiA GENETICS SA's products and services.

Bargaining Power Of Suppliers

SOPHiA GENETICS SA's suppliers are primarily providers of genomic data and sequencing technologies. The company has a diversified supplier base, which reduces the bargaining power of individual suppliers.

Threat Of New Entrants

The genomics industry is rapidly evolving, and new entrants with innovative technologies and business models can potentially disrupt SOPHiA GENETICS SA's market position.

Intensity Of Rivalry

The genomics industry is highly competitive, with several established players and new entrants vying for market share. SOPHiA GENETICS SA's competitive advantage lies in its proprietary algorithms and expertise in genomic data analysis.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 10.94%
Debt Cost 3.95%
Equity Weight 89.06%
Equity Cost 9.80%
WACC 9.16%
Leverage 12.28%

11. Quality Control: SOPHiA GENETICS SA passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Nexus

A-Score: 5.6/10

Value: 2.0

Growth: 7.2

Quality: 7.9

Yield: 0.0

Momentum: 9.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
CompuGroup Medical

A-Score: 4.7/10

Value: 4.6

Growth: 4.2

Quality: 4.1

Yield: 0.6

Momentum: 9.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Equasens

A-Score: 4.2/10

Value: 4.6

Growth: 4.9

Quality: 7.2

Yield: 4.4

Momentum: 1.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Cegedim

A-Score: 4.0/10

Value: 10.0

Growth: 3.7

Quality: 2.3

Yield: 0.0

Momentum: 2.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
SOPHiA GENETICS

A-Score: 3.8/10

Value: 6.8

Growth: 4.6

Quality: 3.7

Yield: 0.0

Momentum: 8.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Surgical Science Sweden

A-Score: 2.9/10

Value: 1.9

Growth: 7.7

Quality: 6.1

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.85$

Current Price

4.85$

Potential

-0.00%

Expected Cash-Flows